What will be the kind of intensive change in pharmaceutical executives in 2020? Heng Rui, Gan Li, Good Doctor Ping-...

Guide: Since 2020, the pharmaceutical industry has been significantly more intensive and focused than usual!---- since this year, a number of well-known pharmaceutical company founders, presidents and other executives have left in a dense number of departuresHengrui senior executives concentrated resignation On July 24, Hengrui Pharmaceuticals announced that the company's deputy general manager Jiang Xinhua, Sun Hui, Liu Jie, MrLi Kejian due to age reasons to apply to resign from the company's deputy general manager, resigned from the above-mentioned positions, Jiang Xinhua, Sun Hui, MrLiu Jie still work in the companyThis personnel change will not affect the normal development of the company's workPrior to his resignation, Hengrui Pharma's 2019 annual report revealed that the four men's terms of office would begin on 16 January 2020 and end on 15 January 2023, with the term of office of the new management also serving for half a yearJiang Xinhua and Li Kejian's pre-tax salaries were 990,000 yuan and 940,000 yuan, respectively, while Sun Hui and Liu Ji's pre-tax salaries were 1.57 million yuan and 1.05 million yuan, respectivelyAs of December 31, 2019, Jiang Xinhua holds 1.3911 million shares, Li Kejian holds 1.2018 million shares, Sun Hui holds 1.551 million shares and Liu Yi holds 1.2683 million sharesSpecifically as follows: some netizens said that Hengrui executives concentrated resignation, or to reduce the holding of shares cashAccording to the relevant regulations, executives in the six months of departure, not to casually reduce their holdingsArticle 12 of the Regulations on the Implementation of the Measures for the Reduction of Shares of Shareholders and Directors, Supervisors and Senior Managers of listed companies on the Shanghai Stock Exchange stipulates: "Where the Directors and Supervisors leave their posts before the expiration of their term of office, they shall abide by the following restrictive provisions within 6 months of the term of office and the expiration of their term of office: 1The shares transferred each year shall not exceed the shares of the Company held by him or her25% of the total; 2Within six months of leaving office, no transfer of its shares in the Company.The total market value of Hengrui Pharmaceuticals has now broken $500 billion, at the close of trading at 95.18 yuan per share at noon today, and the total market value of the above four persons' holdings amounts to 510 million yuanThe flow of executive departures from pharmaceutical companies is common in the industry, and mrHeng's resignation sings are all over the age of 55, and the announcement mentions that the departures of the four were due to age or because of the younger nature of the teamIt is also worth mentioning that on January 16 this year, Sun Hua, founder and chairman of Hengrui Pharmaceuticals, stepped down as chairman of the listed company, and Zhou Yunshu, general manager of the company, took over as chairmanFounder left Gan Li Pharmaceutical management change blood June 29, Gan Li Pharmaceuticals officially landed on the main board of the Shanghai Stock Exchange, after experiencing a number of ups and downs, the total market value in two weeks broke 100 billion, attracting a lot of attention from the industryShortly after, Gan Li Pharmaceuticals issued a notice that MrGan Zhongru, MsWang Damei, MrNing Junjun for personal reasons, respectively, applied to resign the company's general manager, deputy general manager, finance headGan Li Pharmaceuticals said that after resigning as a senior manager of the company, DrGan Zhongru and MsWang Damei will lead the research and development team to devote themselves to the company's new product development and technological innovation workAt the same time, Gan Li Pharmaceutical's new management team officially debuted, in which Du Kai as general manager, in addition to the financial head Sun Cheng for the new joining, the company also promoted from the inside Lawrence Allan Hill, Wang Bin, Yuan Zifei and Cheng 4 deputy general managersGan Li Pharmaceuticals' former management quit the front line and was replaced by a new teamIt is understood that the change in Gan Li's management was not sudden, after The addition of Tukai, Lawrence Allan Hill and others to become representative young management teamAccording to the data, Gan Li Pharmaceutical founder Gan Zhongru was born in 1948, doctoral student, graduated from Michigan State University, the former chairman of the company, general managerThe new general manager Du Kai was born in 1977, graduated from Loughborough University in the United Kingdom, with 20 years of overseas business experience, since 2008 joined Ganli Pharmaceuticals, has served as director of the international department, Ganli Pharmaceuticals Russia, The Director of The United States Company, in 2016 was promoted to Deputy General ManagerDrug executives leave foer, Kangmei, Ping An good doctor. The flow of pharmaceutical companies is not uncommon, but since 2020, the pharmaceutical industry has been significantly more intensive and concentrated in jobs than usual According to China Net Finance, in the first half of 2020, about 69 listed pharmaceutical executives with revenues of more than 100 million have been adjusted The reasons for the departure of pharmaceutical executives are mostly personal reasons, work reasons, family reasons, age reasons, etc Industry insiders point out that this may be affected by this year's new crown outbreak and other sudden factors In addition, with the introduction of policies such as 4-7-belt procurement and health-care control fees, the entire pharmaceutical industry is facing a transformation that will also accelerate the flow of pharmaceutical executives The following are the well-known pharmaceutical companies that have left this year and the founders, presidents and so on: On January 19, Dong'a Gum announced that, due to retirement at an age, Qin Yufeng applied to resign from the 9th Board of Directors, President and The Company's legal representative positions, and resigned from the 9th Board of Directors Strategy Committee and Nomination Committee On February 28, Jiuzhitang announced that the Board of Directors had received reports of the resignations of Director Mr Liu Guochao, Director and Deputy General Manager Mr Sheng Lockzhu, Director Mr Li Jinsong, Supervisor Ms Li Wei and Supervisor Ms Liu Shuxia On April 2, Renfu Pharmaceuticals announced that Wang Xuehai had offered to resign as chairman of Renfu Pharmaceuticals because of the adjustment of the division of work, and Li Jie had offered to resign as president of Renfu Pharmaceuticals because of the adjustment of the division of work Nominated by the chairman of Renfu Pharmaceuticals, renfu Pharmaceuticals Board of Directors decided to appoint the company's director, Vice President Deng Xiafei as president On April 10, Beijing Ted Pharmaceuticals news said that the company's president Kong Tai for personal reasons to resign, the company appointed Sun Aerohang as Beijing Ted Pharmaceutical acting president, full yare to take charge of Ted Pharmaceuticals management, reported to Beijing Ted Pharmaceutical Chairman Zheng Xiangling, effective immediately On May 18, Ping An Good Doctor announced that the board of directors had decided to remove Wang Tao from his position as chairman, executive director and chief executive officer At the same time, Mr Fang Weihao has been appointed as The Executive Director, Chairman of the Interim Board of Directors and Chief Executive Officer Soon after, the company's chief executive, chief operating officer, chief product officer, chief technology officer, etc were removed from office, "Ali" executive team all quit Ping An good doctor later issued a supplementary announcement that Wang Tao in the performance of management duties did not meet the expectations of the board of directors, the board decided to remove Wang Tao chairman of the board and other duties On June 1, Fosun Pharma announced that For personal reasons, Li Jianqing applied to the company's board of directors to resign as vice president This year, Fosun Hashadi has had several executives leave Vice President Dai Kun resigned in April and Hequn Yin, senior vice president, resigned in May for family reasons, and two non-executive directors, Liang Jianfeng and Wang Can, resigned in January In addition, there are also suspected financial fraud, resulting in management changes On May 14, the China Securities Regulatory Commission (CSRC) made a decision on the case of Kangmei Pharmaceuticals' inflated revenue, in which six principals were banned from the securities market for 10 to 10 years, including Ma Xingtian, chairman and general manager of the company; Xu Dongxuan, vice chairman and executive vice-president of the company; Lin Guoxiong, the company's deputy general manager; and Wen Shaosheng, the company's finance director Subsequently, Kangmei Pharmaceuticals issued a notice that the above five related personnel and the company's supervisory board chairman Luo Jiaqian, the company's staff supervisor Ma Huanzhou has left